Click on the links below to view abstracts and posters presented at this congress. All copyright remains that of the copyright holder. This page will be available for a limited period after the congress.
Poster presentations
Wednesday 18 September 2019
1:15 PM–2:15 PM PS 004 Additional spotlights on cardiovascular disease Poster Hall
1:15 PM–2:15 PM PS 070 The potential of new basal insulins Poster Hall
Poster presentation 302 Buse
Outcomes of type 2 diabetes clustering replicated in the DEVOTE trial
View PDF
Poster presentation 893 Jendle
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes in a Swedish setting
View PDF
12:00 PM–1:00 PM PS 057 Incretin-based therapies: clinical studies Poster Hall
Poster presentation 770 Rea
Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: a 26-week, randomised, double-blind, placebo-controlled trial
View PDF
Poster presentation 894 Ericsson
Cost-effectiveness of insulin degludec vs. insulin glargine U100 in type 1 diabetes in a Swedish setting after one year
View PDF
1:15 PM–2:15 PM PS 082 Promising therapeutic options for diabetic kidney disease Poster Hall
Poster presentation 773 Viljoen
Efficacy and safety of semaglutide by baseline BMI in SUSTAIN 1–5 and 7
View PDF
Poster presentation 998 Perkovic
Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER
View PDF
Poster presentation 775 Pratley
Efficacy and safety of once-weekly semaglutide low dose 0.5 mg vs. once-weekly dulaglutide high dose 1.5 mg in type 2 diabetes: a post hoc analysis of SUSTAIN 7
View PDF
Poster presentation 776 Ludvik
Efficacy and safety of semaglutide by background sodium-glucose cotransporter-2 inhibitor: a post hoc analysis of SUSTAIN 9
View PDF
1:15 PM–2:15 PM PS 100 Treatment of cardiovascular disease Poster Hall
Poster presentation 1164 Verma (Leiter)
Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
View PDF
Poster presentation 777 Overgaard
Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide
View PDF